Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 58%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is expected to see significant growth in revenues and market share through collaborations, acquisitions, and expansions. The company has faced regulatory uncertainty and may require additional financing before reaching positive cash flow. With a strong presence in both liquid biopsy and tissue-based genomic profiling, along with plans to launch new tests, GH remains a strong contender in the precision oncology diagnostics market but may need to increase sales and marketing efforts to stay ahead of the competition.

Bears say

Guardant Health is a leading provider of liquid-based cancer tests, with a strong market position and a diverse portfolio of products and services. However, the company faces challenges in a growingly competitive market with other companies entering the space and potentially limiting Guardant's ability to command a price premium. Additionally, the company's long-term growth potential may be impacted by negative regulatory and payer dynamics in the reproductive health market. As a result, the outlook for Guardant's stock is negative as these factors could potentially lead to lower profitability and slower growth than expected.

GH has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 58% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 19 analysts, GH has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $119.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $119.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.